Order Samples Mobile

To order samples, get more co-pay cards, or schedule a visit from your Avadel representative, please fill out this form.
NOCTIVA offers 2 microdoses of desmopressin

When kidneys work overtime
to produce too much urine at night,
think NOCTIVA

NOCTIVA™ (desmopressin acetate) Nasal Spray decreased the amount of times patients with nocturnal polyuria woke up during the night to urinate.1

ABOUT NOCTIVA
WHY NOCTIVA?
spray

Patented formulation and spray pattern that deliver a microdose of desmopressin.1,2

Why NOCTIVA Is Unique
kidneys

Works in the kidneys, the source of excess urine production.1

How NOCTIVA Works
efficacy

Demonstrated efficacy and safety in 2 clinical trials with 1045 patients.1

See NOCTIVA Data

Avadel is committed to helping patients access the treatment they need.

HELP YOUR PATIENTS SAVE

Avadel is committed to education. Hear from your peers and check back for upcoming live webinars.

Resources
Receive Updates

Please fill out the form to receive updates about NOCTIVA first.

All fields are required.

References: 1. NOCTIVA [package insert]. Chesterfield, MO: Avadel Specialty Pharmaceuticals, LLC; 2017. 2. Data on file. Avadel Specialty Pharmaceuticals, LLC.

INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: HYPONATREMIA

See full prescribing information for complete boxed warning.

  • NOCTIVA can cause hyponatremia, which may be life-threatening if severe.
  • NOCTIVA is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids.
  • Ensure serum sodium is normal before starting or resuming NOCTIVA. Measure serum sodium within seven days and approximately one month after initiating therapy or increasing the dose, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia.
  • If hyponatremia occurs, NOCTIVA may need to be temporarily or permanently discontinued.

Indications and usage

NOCTIVA is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

Limitation of Use: Not studied in patients younger than 50 years of age.

Contraindications

  • Hyponatremia or a history of hyponatremia
  • Polydipsia
  • Primary nocturnal enuresis
  • Concomitant use with loop diuretics or systemic or inhaled glucocorticoids
  • Estimated glomerular filtration rate below 50 mL/min/1.73 m2
  • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
  • During illnesses that can cause fluid or electrolyte imbalance
  • New York Heart Association (NYHA) Class II-IV congestive heart failure
  • Uncontrolled hypertension

Warnings and Precautions

  • Fluid retention: Not recommended in patients at risk of increased intracranial pressure or history of urinary retention. Monitor volume status in patients with NYHA Class I congestive heart failure.
  • Nasal conditions: Discontinue in patients with concurrent nasal conditions that may increase absorption, until resolved.

Adverse Reactions

Common adverse reactions in clinical trials (incidence >2%) included nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension / blood pressure increased, back pain, epistaxis, bronchitis and dizziness.

Drug Interactions

Monitor serum sodium more frequently when NOCTIVA is concomitantly used with drugs that may cause water retention and increase the risk for hyponatremia (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, nonsteroidal anti-inflammatories, lamotrigine and carbamazepine).

Use in Specific Populations

  • Pregnancy: Use of NOCTIVA is not recommended.
  • Pediatric: Do not use NOCTIVA for primary nocturnal enuresis in children.

To report SUSPECTED ADVERSE REACTIONS, contact Avadel at 1-877-638-4579 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Are You a
Healthcare Provider?
Yes No